Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1

BACKGROUND: Adjuvant therapy decisions in early breast cancer are based on accurate risk assessment. Urokinase plasminogen activator (uPA) and plaminogen activator inhibitor-1 (PAI-1) have been the first biomarkers in hormone receptor (HR) positive breast cancer to reach highest level of evidence. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Ettl, Johannes, Klein, Evelyn, Hapfelmeier, Alexander, Grosse Lackmann, Kirsten, Paepke, Stefan, Petry, Christoph, Specht, Katja, Wolff, Laura, Höfler, Heinz, Kiechle, Marion
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587293/
https://www.ncbi.nlm.nih.gov/pubmed/28877230
http://dx.doi.org/10.1371/journal.pone.0183917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587293/
https://www.ncbi.nlm.nih.gov/pubmed/28877230
http://dx.doi.org/10.1371/journal.pone.0183917

Ejemplares similares